Practice guideline summary: Treatment of restless legs syndrome in adults

Neurology

Volumn 87, Issue 24, 2016, Pages 2585-2593

  Winkelman, John W ^a   Armstrong, Melissa J ^b   Allen, Richard P ^c   Chaudhuri, K Ray ^d   Ondo, William ^e   Trenkwalder, Claudia ^f   Zee, Phyllis C ^g   Gronseth, Gary S ^h   Gloss, David ⁱ   Zesiewicz, Theresa ^j  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^f UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^g NORTHWESTERN UNIVERSITY   (United States)

^h UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

ⁱ CAMC Health System   (United States)

^j UNIVERSITY OF SOUTH FLORIDA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CABERGOLINE; FERRIC CARBOXYMALTOSE; FERROUS SULFATE; GABAPENTIN ENACARBIL; LEVODOPA; NALOXONE; OXYCODONE; PRAMIPEXOLE; PREGABALIN; ROPINIROLE; ROTIGOTINE; DOPAMINE RECEPTOR STIMULATING AGENT; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL PRACTICE; DEPRESSION; DRUG USE; EVIDENCE BASED PRACTICE; EXERCISE; HEMODIALYSIS; HUMAN; IRON THERAPY; NEAR INFRARED SPECTROSCOPY; PATIENT COMPLIANCE; PERIODIC LIMB MOVEMENT DISORDER; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; SLEEP; TRANSCRANIAL DIRECT CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; VITAMIN SUPPLEMENTATION; MEDICAL SOCIETY;

ADULT; DOPAMINE AGENTS; DOPAMINE AGONISTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RESTLESS LEGS SYNDROME; SOCIETIES, MEDICAL; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 85006010317     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003388     Document Type: Article

References (40)

1. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Inter Med 2005;165:1286-1292
2. Zucconi M, Ferri R, Allen R, et al; for the International Restless Legs Syndrome Study Group. The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). Sleep Med 2006;7:175-183
3. Winkelman JW, Redline S, Baldwin CM, Resnick HE, Newman AB, Gottlieb DJ. Polysomnographic and health-related quality of life correlates of restless legs syndrome in the Sleep Heart Health Study. Sleep 2009;32: 772-778
4. Hornyak M. Depressive disorders in restless legs syndrome: epidemiology, pathophysiology and management. CNS Drugs 2010;24:89-98
5. Reinhold T, Müller-Riemenschneider F, Willich SN, Brüggenjürgen B. Economic and human costs of restless legs syndrome. Pharmacoeconomics 2009;27:267-279
6. Allen RP, Bharmal M, Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord 2011;26:114-120
7. Garcia-Borreguero D, Williams AM. Dopaminergic augmentation of restless legs syndrome. Sleep Med Rev 2010; 14:339-346
8. American Academy of Neurology. Clinical Practice Guideline Process Manual. 2004 ed. St. Paul: American Academy of Neurology; 2004:1-57
9. Allen RP. Minimal clinically significant change for the International Restless Legs Syndrome Study Group rating scale in clinical trials is a score of 3. Sleep Med 2013;14:1229
10. Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY; for the TREAT RLS US Study Group. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006;81:17-27
11. Allen R, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004;27:907-914
12. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al; for the Therapy with Ropinirole; Efficacy and Tolerability in RLS 1 Study Group. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75:92-97
13. Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K; for the TREAT RLS 2 (Therapy with Ropinirole: Efficacy And Tolerability in RLS 2) Study Group. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004;19:1414-1423
14. Benes H, Mattern W, Peglau I, et al. Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebocontrolled study. J Neurol 2011;258:1046-1054
15. Giorgi L, Asgharian A, Hunter B. Ropinirole in patients with restless legs syndrome and baseline IRLS total scores $24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension. Clin Ther 2013;35:1321-1336
16. Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006;67:1034-1039
17. Ma JF, Wan Q, Hu XY, et al. Efficacy and safety of pramipexole in Chinese patients with restless legs syndrome: results from a multi-center, randomized, doubleblind, placebo-controlled trial. Sleep Med 2011;13:58-63
18. Zhang J, Liu B, Zheng Y, Chu T, Yang Z. Pramipexole for Chinese people with primary restless legs syndrome: a 12-week multicenter, randomized, double-blind study. Sleep Med 2015;16:181-185
19. Ferini-Strambi L, Aarskog D, Partinen M, et al. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med 2008;9: 874-881
20. Partinen M, Hirvonen K, Jama L, et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study: the PRELUDE study. Sleep Med 2006;7:407-417
21. Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al; for the Pramipexole RLS Study Group. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 2007;22:213-219
22. Jama L, Hirvonen K, Partinen M, et al. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance. Sleep Med 2009;10:630-636
23. Montagna P, Hornyak M, Ulfberg J, et al. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Sleep Med 2011;12:34-40
24. Allen RP, Chen C, Garcia-Borreguero D, et al. Pregabalin versus pramipexole for restless legs syndrome. N Engl J Med 2014;370:635-643
25. Garcia-Borreguero D, Patrick J, DuBrava S, et al. Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep 2014;37:635-643
26. Stiasny-Kolster K, Kohnen R, Schollmayer E, Moller JC, Oertel WH; for the Rotigotine Sp 666 Study Group. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004;19:1432-1438
27. Oertel WH, Benes H, Garcia-Borreguero D, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med 2010;11:848-856
28. Hening WA, Allen RP, Ondo WG, et al; for the SP792 Study Group. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebocontrolled trial in the United States. Mov Disord 2010;25:1675-1683
29. Inoue Y, Shimizu T, Hirata K, et al; for the Rotigotine Trial Group. Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study. Sleep Med 2013;14:1085-1091
30. Trenkwalder C, Benes H, Poewe W, et al; for the SP790 Study Group. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008;7:595-604
31. Benes H, Kurella B, Kummer J, Kazenwadel J, Selzer R, Kohnen R. Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. Sleep 1999;22:1073-1081
32. Trenkwalder C, Stiasny K, Pollmächer T, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 1995;18:681-688
33. Brodeur C, Montplaisir J, Godbout R, Marinier R. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology 1988;38:1845-1848
34. Eisensehr I, Ehrenberg BL, Rogge Solti S, Noachtar S. Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid. J Neurol 2004;251:579-583
35. Kushida CA, Walters AS, Becker P, et al; for the XP021 Study Group. A randomized, double-blind, placebocontrolled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009;32:159-168
36. Walters AS, Ondo WG, Kushida CA, et al; for the XP045 Study Group. Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebocontrolled trial. Clin Neuropharmacol 2009;32:311-320
37. Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW. for the XP052 Study Group. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 2009;72:439-446
38. Lee DO, Ziman RB, Perkins AT, Poceta JS, Walters AS, Barrett RW, for the XP053 Study Group. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med 2011;7: 282-292
39. Allen R, Chen C, Soaita A, et al. A randomized, doubleblind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med 2010;11:512-519
40. Garcia-Borreguero D, Larrosa O, Williams AM, et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology 2010;74: 1897-1904